Evidence map›Paper›PMID 32279539›Full record

GuidelineCirculation2020

Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association.

Suzanne V Arnold, Deepak L Bhatt, Gregory W Barsness, Alexis L Beatty, Prakash C Deedwania, Silvio E Inzucchi, Mikhail Kosiborod, Lawrence A Leiter, Kasia J Lipska, Jonathan D Newman and 2 more

Open access · bronzeAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 9 pooled it
24.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 9 syntheses or guidelines pooled it, 288 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Trial
  18. Trial
  19. Article
  20. Article

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 3 countries.

Suzanne V Arnold
Deepak L Bhatt
Gregory W Barsness
Alexis L Beatty
Prakash C Deedwania
Silvio E Inzucchi
Mikhail Kosiborod
Lawrence A Leiter
Kasia J Lipska
Jonathan D Newman
Francine K Welty
American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology
American Heart Association · USSt. Gregory's University · US

Funding

NHLBI NIH HHS K23 HL125991
6 · The paper itself

Abstract

Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development and progression of the disease. Over the past decade, a number of factors have shifted that have forced the cardiology community to reconsider the role of T2DM in CAD. First, in addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a number of treatment choices for CAD. In this document, we discuss the role that T2DM has in the selection of testing for CAD, in medical management (both secondary prevention strategies and treatment of stable angina), and in the selection of revascularization strategy. Second, although glycemic control has been recommended as a part of comprehensive risk factor management in patients with CAD, there is mounting evidence that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. In this document, we discuss the role of glycemic management (both in intensity of control and choice of medications) in cardiovascular outcomes. It is becoming clear that the cardiologist needs both to consider T2DM in cardiovascular treatment decisions and potentially to help guide the selection of glucose-lowering medications. Our statement provides a comprehensive summary of effective, patient-centered management of CAD in patients with T2DM, with emphasis on the emerging evidence. Given the increasing prevalence of T2DM and the accumulating evidence of the need to consider T2DM in treatment decisions, this knowledge will become ever more important to optimize our patients' cardiovascular outcomes.

Indexed as

Risk Reduction BehaviorAmerican Heart AssociationClinical Decision-MakingComorbidityConsensusCoronary Artery DiseaseDiabetes Mellitus, Type 2HumansHypoglycemic AgentsMyocardial RevascularizationPatient-Centered CareRisk AssessmentRisk FactorsSecondary PreventionTreatment OutcomeUnited StatesHypoglycemic AgentsAHA Scientific Statementsblood glucosecoronary artery diseasediabetes mellitus, type 2patient-centered caresecondary prevention

Identifiers

PMID32279539
PMCPMC12204403
OpenAlexW3015405225

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.